Supraciliary micro-stent implantation for open-angle glaucoma failing topical therapy: 1-year results of a multicenter study

Julian García-Feijoo, Magda Rau, Swaantje Grisanti, Salvatore Grisanti, Helmut Höh, Carl Erb, Pravoslava Guguchkova, Iqbal Ahmed, Günther Grabner, Herbert Reitsamer, Tarek Shaarawy, Tsontcho Ianchulev

Research output: Contribution to journalArticlepeer-review

90 Scopus citations

Abstract

Purpose To evaluate the safety and efficacy of a supraciliary micro-stent (CyPass Micro-Stent; Transcend Medical, Menlo Park, California, USA) for surgical treatment of glaucoma in patients refractory to topical medications. Design Multicenter, single-arm interventional study. Methods Patients with open-angle glaucoma (Shaffer Grade 3 and 4) and uncontrolled medicated intraocular pressure (IOP) >21 mm Hg at baseline and candidates for conventional glaucoma surgery were enrolled. Glaucoma medications were discontinued at surgery and resumed at investigator discretion. CyPass Micro-Stent implantation was completed in all patients using a standard clear corneal approach. Adverse events, postoperative IOP changes, and need for IOP-lowering medications during the first 12 postoperative months (12M) were monitored. Results Sixty-five eyes were enrolled, and 55 were available at 12M, accounting for loss to follow-up and early termination. Baseline IOP was 24.5 ± 2.8 mm Hg, and the mean number of medications recorded was 2.2 ± 1.1. There were no serious intraoperative events or major adverse events (eg, retinal or choroidal detachment, persistent uveitis, persistent hyphema, hypotony maculopathy). The most common adverse events included IOP increases >30 mm Hg beyond 1 month (11%, 7/65), transient hyphema (6%, 4/65), and cataract progression (12%, 5/41 phakic eyes). Mean IOP was 16.4 ± 5.5 mm Hg at 12 months - a 34.7% reduction (P <.0001). Mean medication usage also decreased from baseline to a mean of 1.4 ± 1.3 medications at 12M (P =.002). In eyes originally indicated for conventional glaucoma surgery, no secondary surgery was performed in 83% (53/64). Conclusion Supraciliary stenting with the CyPass Micro-Stent effectively lowers IOP as a surgical treatment for glaucoma, precluding the need for more invasive glaucoma surgery in >80% of patients at 1 year, thereby reducing postoperative glaucoma surgical complications.

Original languageEnglish
Pages (from-to)1075-1081.e1
JournalAmerican Journal of Ophthalmology
Volume159
Issue number6
DOIs
StatePublished - 1 Jun 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'Supraciliary micro-stent implantation for open-angle glaucoma failing topical therapy: 1-year results of a multicenter study'. Together they form a unique fingerprint.

Cite this